Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Mandala

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026Alexander J Stratigos, Clio Dessinioti, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026Alexander J Stratigos, Clio Dessinioti, Claus Garbe, et al.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Nature Genetics|April 29, 2020
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibilityMaria Teresa Landi, D Timothy Bishop, Stuart MacGregor, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026Alexander J Stratigos, Clio Dessinioti, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026Alexander J Stratigos, Clio Dessinioti, Claus Garbe, et al.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Nature Genetics|April 29, 2020
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibilityMaria Teresa Landi, D Timothy Bishop, Stuart MacGregor, et al.
Pageof 7